Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2013 | 04:44pm CEST
   By Melodie Warner 
 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
08/18 REGENERON PHARMACEUTICALS : `s (REGN) RSV Drug Suptavumab Fails NURSERY Trial
08/15 TWO FAILED TRIALS : Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) and Regeneron Ph..
08/14DJHot Stocks to Watch in the U.S. and Canada
08/14 REGENERON PHARMACEUTICALS : to Discontinue Development of Suptavumab for Respira..
08/11 REGENERON PHARMACEUTICALS : Baltimore Native Awarded Regeneron Prize for Medical..
08/10 REGENERON PHARMACEUTICALS : Accessing the Regeneron Second Quarter 2017 Financia..
08/10 REGENERON PHARMACEUTICALS : Researchers Submit Patent Application, "Fucosylation..
08/03 REGENERON PHARMACEUTICALS : "Use of a Vegf Antagonist to Treat Angiogenic Eye Di..
08/03 REGENERON PHARMACEUTICALS : Accessing the Regeneron Second Quarter 2017 Financia..
08/03 REGENERON PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
More news
News from SeekingAlpha
08/21 Seeking Confirmations - U.S. Stock Market
08/21 OPHTHOTECH : 3 Strikes And It's Out?
08/17 Evercore ISI initiates 14 bullish calls, 9 neutral
08/15 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 15, 2017
08/14 Regeneron's suptavumab fails to beat placebo in preventing RSV infection in i..
Financials ($)
Sales 2017 5 746 M
EBIT 2017 2 358 M
Net income 2017 1 328 M
Finance 2017 2 375 M
Yield 2017 -
P/E ratio 2017 41,76
P/E ratio 2018 38,36
EV / Sales 2017 8,51x
EV / Sales 2018 7,72x
Capitalization 51 288 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 494 $
Spread / Average Target 3,3%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS29.98%51 288
AMGEN16.32%124 096
CELGENE CORPORATION10.09%101 932
GILEAD SCIENCES0.70%95 777
VERTEX PHARMACEUTICALS111.05%39 199
ACTELION22.00%30 388